A Phase 3 Study of MH004 Ointment in Patients With Mild to Moderate Atopic Dermatitis

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
This is a multicenter, randomized, double-blind, vehicle-controlled phase III study of MH004 Ointment with a 44-week open-label long-term safety extension period. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and primary efficacy of MH004 Ointment in adolescents and adults with mild to moderate atopic dermatitis.
Epistemonikos ID: b5305ff2109ba8c217be249acde8e2f492c9a6aa
First added on: Sep 23, 2025